Time until relapse after augmentation with single-dose ketamine in treatment-resistant depression

Psychiatry Clin Neurosci. 2018 Aug;72(8):623. doi: 10.1111/pcn.12675. Epub 2018 Jun 19.

Authors

Rodrigo Pérez-Esparza^{1

2}, Teresa Corona³, Ramiro Gilberto Ruiz-García¹, Nelcy Oñate-Cadena¹, Camilo de la Fuente-Sandoval^{1

4}, Jesús Ramírez-Bermúdez¹

Affiliations

¹ Department of Neuropsychiatry, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
² Addiction Research Laboratory, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
³ Department of Neurodegenerative Diseases, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.
⁴ Laboratory of Experimental Psychiatry, National Institute of Neurology and Neurosurgery, Mexico City, Mexico.

PMID: 29744959
DOI: 10.1111/pcn.12675

No abstract available

Publication types

Clinical Trial
Letter

MeSH terms

Adult
Antidepressive Agents / administration & dosage
Antidepressive Agents / pharmacology*
Depressive Disorder, Treatment-Resistant / drug therapy*
Drug Synergism
Excitatory Amino Acid Antagonists / administration & dosage
Excitatory Amino Acid Antagonists / pharmacology*
Humans
Ketamine / administration & dosage
Ketamine / pharmacology*
Outcome Assessment, Health Care*
Recurrence
Severity of Illness Index

Substances

Antidepressive Agents
Excitatory Amino Acid Antagonists
Ketamine